Triplet therapy overcomes 3rd-EGFR TKl-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation  

作　　者：Kaibo Ding Zhongsheng Peng Yanjun Xu 

机构地区：[1]Department of Medical Thoracic Oncology,Zhejiang Cancer Hospital,Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou,Zhejiang 310022,China [2]Postgraduate Training Base Alliance of Wenzhou Medical University(Zhejiang Cancer Hospital),Hangzhou,Zhejiang 310022,China

出　　处：《Genes & Diseases》2025年第2期1-3,共3页基因与疾病(英文)

基　　金：supported by the Natural Scientific Foundation of Zhejiang Province,China (No.LTGY23H160007).

摘　　要：Epidermal growth factor receptor(EGFR)-positive nonsmall cell lung cancer is a dynamic entity,with tumor progression and resistance to tyrosine kinase inhibitors(TKls)stemming from the accumulation of mutations over time and across different disease sites,leading to temporal and spatial heterogeneity.

关 键 词：heterogeneity. LUNG OVERCOME 

分 类 号：R73[医药卫生—肿瘤]